Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
First Claim
Patent Images
1. A purified cyclodextrin derivative composition which comprises a cyclodextrin derivative of formula ##STR3## wherein:
- n is 4, 5 or 6;
R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each, independently, O- or a O--(C2-6 alkylene)--SO3- group, and at least one of R1 and R2 is, independently, said O--(C2-6 alkylene)--SO3- group; and
S1, S2, S3, S4, S5, S6, S7, S8 and S9 are each, independently, a pharmaceutically acceptable cation, and wherein said composition shows an absence of underivatized cyclodextrin as measured by thin-layer chromatography.
2 Assignments
0 Petitions
Accused Products
Abstract
Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.
-
Citations
45 Claims
-
1. A purified cyclodextrin derivative composition which comprises a cyclodextrin derivative of formula ##STR3## wherein:
- n is 4, 5 or 6;
R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each, independently, O- or a O--(C2-6 alkylene)--SO3- group, and at least one of R1 and R2 is, independently, said O--(C2-6 alkylene)--SO3- group; and S1, S2, S3, S4, S5, S6, S7, S8 and S9 are each, independently, a pharmaceutically acceptable cation, and wherein said composition shows an absence of underivatized cyclodextrin as measured by thin-layer chromatography. - View Dependent Claims (2, 3, 4, 5, 6, 7, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 43, 45)
- n is 4, 5 or 6;
-
8. A composition comprising a drug complexed to a cyclodextrin derivative of formula (2):
- ##STR4## wherein;
n=4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each at least one of R1 and R2 is, independently, said O--(C 2-6 alkylene)--SO3- group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation; wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin. - View Dependent Claims (9, 10, 11, 12, 13, 36, 37, 38, 39, 40)
- ##STR4## wherein;
-
14. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a clathrate complex comprising a drug complexed to a cyclodextrin derivative of formula (2):
- ##STR5## wherein;
n=4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently O- or a O--(C2-6 alkylene)--SO3- group, and at least one of R1 and R2 is, independently, said O--(C2-6 alkylene)--SO3- group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation; wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin. - View Dependent Claims (15, 41, 42, 44)
- ##STR5## wherein;
-
16. A delayed release pharmaceutical composition, comprising a drug complexed to a purified cyclodextrin derivative of formula (2):
- ##STR6## wherein;
n=4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently O- or a O--(C2-6 alkylene)SO3- group, and at least one of R1 and R2 is, independently said O--(C2-6 alkylene)--SO3- group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation.
- ##STR6## wherein;
Specification